Scholarlink

Abstract <p><i>Xanthoceras sorbifolia</i> Bunge Oil (XSBO) is an extract from a natural medicinal plant that has been studied for its potential to improve various diseases. Tic disorder (TD) is a common neurodevelopmental disorder in children, with a complex pathogenesis and currently no effective treatment. This study employed network pharmacology and molecular docking techniques to explore the potential targets and mechanisms of action of XSBO in the prevention and treatment of TD. Through PPI network analysis, the glutamate receptor-related genes GRIN2B, GRM5, and GRIN1 were identified as key targets for the neuroprotective and TD-preventive effects of XSBO. Molecular docking results further confirmed that the major active components of XSBO have good binding affinity with these core targets. Animal experiments showed that XSBO could significantly reduce the mRNA expression of GRIN2B, GRM5, and GRIN1 in the striatum of TD rat models. These results suggest that XSBO may exert its preventive and therapeutic effects on TD through the regulation of the glutamatergic pathway.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Experimental Study and Exploration of the Mechanism of Action of Natural Medicinal Plant Extract Xanthoceras sorbifolia Bunge Oil in Ameliorating Tic Disorder

  • 期刊论文

  • 发表日期：

    2026年3月1日

查看全文
  • Mingyue Zhang,
  • Yinghui Zhang,
  • Xue Xiao,
  • Qinqiang Long

摘要

Abstract

Xanthoceras sorbifolia Bunge Oil (XSBO) is an extract from a natural medicinal plant that has been studied for its potential to improve various diseases. Tic disorder (TD) is a common neurodevelopmental disorder in children, with a complex pathogenesis and currently no effective treatment. This study employed network pharmacology and molecular docking techniques to explore the potential targets and mechanisms of action of XSBO in the prevention and treatment of TD. Through PPI network analysis, the glutamate receptor-related genes GRIN2B, GRM5, and GRIN1 were identified as key targets for the neuroprotective and TD-preventive effects of XSBO. Molecular docking results further confirmed that the major active components of XSBO have good binding affinity with these core targets. Animal experiments showed that XSBO could significantly reduce the mRNA expression of GRIN2B, GRM5, and GRIN1 in the striatum of TD rat models. These results suggest that XSBO may exert its preventive and therapeutic effects on TD through the regulation of the glutamatergic pathway.